Free Trial

This company has been marked as potentially delisted and may not be actively trading.

Flex Pharma (FLKS) Competitors

Flex Pharma logo

FLKS vs. GANX, SKYE, ACET, IMMX, RENB, FBIO, VRCA, PEPG, CUE, and ATNM

Should you be buying Flex Pharma stock or one of its competitors? The main competitors of Flex Pharma include Gain Therapeutics (GANX), Skye Bioscience (SKYE), Adicet Bio (ACET), Immix Biopharma (IMMX), Renovaro (RENB), Fortress Biotech (FBIO), Verrica Pharmaceuticals (VRCA), PepGen (PEPG), Cue Biopharma (CUE), and Actinium Pharmaceuticals (ATNM). These companies are all part of the "medical" sector.

Flex Pharma vs.

Gain Therapeutics (NASDAQ:GANX) and Flex Pharma (NASDAQ:FLKS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their valuation, community ranking, risk, dividends, earnings, media sentiment, analyst recommendations, institutional ownership and profitability.

Gain Therapeutics has a beta of 0.17, meaning that its stock price is 83% less volatile than the S&P 500. Comparatively, Flex Pharma has a beta of 1.65, meaning that its stock price is 65% more volatile than the S&P 500.

Flex Pharma received 322 more outperform votes than Gain Therapeutics when rated by MarketBeat users. However, 73.58% of users gave Gain Therapeutics an outperform vote while only 73.23% of users gave Flex Pharma an outperform vote.

CompanyUnderperformOutperform
Gain TherapeuticsOutperform Votes
39
73.58%
Underperform Votes
14
26.42%
Flex PharmaOutperform Votes
361
73.23%
Underperform Votes
132
26.77%

Flex Pharma has higher revenue and earnings than Gain Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Gain Therapeutics$50K1,052.26-$22.27M-$0.86-2.07
Flex Pharma$840K16.73-$21.92MN/AN/A

12.0% of Gain Therapeutics shares are held by institutional investors. Comparatively, 14.4% of Flex Pharma shares are held by institutional investors. 7.2% of Gain Therapeutics shares are held by company insiders. Comparatively, 7.6% of Flex Pharma shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

In the previous week, Gain Therapeutics had 16 more articles in the media than Flex Pharma. MarketBeat recorded 16 mentions for Gain Therapeutics and 0 mentions for Flex Pharma. Gain Therapeutics' average media sentiment score of 0.71 beat Flex Pharma's score of 0.00 indicating that Gain Therapeutics is being referred to more favorably in the media.

Company Overall Sentiment
Gain Therapeutics Positive
Flex Pharma Neutral

Gain Therapeutics has a net margin of 0.00% compared to Flex Pharma's net margin of -1,208.42%. Flex Pharma's return on equity of -98.04% beat Gain Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Gain TherapeuticsN/A -203.91% -128.05%
Flex Pharma -1,208.42%-98.04%-83.37%

Gain Therapeutics presently has a consensus target price of $8.20, indicating a potential upside of 360.67%. Given Gain Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Gain Therapeutics is more favorable than Flex Pharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Gain Therapeutics
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
3.17
Flex Pharma
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

Summary

Gain Therapeutics beats Flex Pharma on 9 of the 17 factors compared between the two stocks.

Get Flex Pharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for FLKS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FLKS vs. The Competition

MetricFlex PharmaPharmaceutical Preparations IndustryMedical SectorNASDAQ Exchange
Market Cap$14.05M$6.47B$5.31B$8.28B
Dividend YieldN/A2.64%5.20%4.10%
P/E RatioN/A8.9026.7319.58
Price / Sales16.73257.08387.44119.65
Price / CashN/A65.8538.2534.62
Price / Book1.526.406.744.47
Net Income-$21.92M$143.98M$3.23B$248.22M

Flex Pharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FLKS
Flex Pharma
N/A$0.78
-0.3%
N/A+58.6%$14.05M$840,000.000.004
GANX
Gain Therapeutics
1.966 of 5 stars
$1.93
+0.5%
$8.20
+324.9%
-26.1%$56.79M$50,000.00-1.7520News Coverage
Analyst Revision
SKYE
Skye Bioscience
1.1081 of 5 stars
$1.94
+12.1%
$16.60
+755.7%
-82.7%$56.07MN/A-2.5211Analyst Forecast
ACET
Adicet Bio
2.5644 of 5 stars
$0.67
-7.4%
$7.50
+1,022.8%
-55.9%$55.25M$24.99M-0.3990
IMMX
Immix Biopharma
1.936 of 5 stars
$1.98
-5.3%
$7.00
+253.5%
+12.1%$55.11MN/A-2.339News Coverage
Gap Down
RENB
Renovaro
0.8177 of 5 stars
$0.34
+3.7%
N/A-64.5%$53.20MN/A-0.3620News Coverage
Gap Up
High Trading Volume
FBIO
Fortress Biotech
1.7022 of 5 stars
$1.74
+5.5%
$21.00
+1,106.9%
-7.5%$51.45M$57.68M-0.57170News Coverage
Analyst Revision
VRCA
Verrica Pharmaceuticals
4.2285 of 5 stars
$0.55
+8.6%
$9.50
+1,627.3%
-93.1%$50.85M$7.57M-0.3040News Coverage
Analyst Upgrade
Gap Down
PEPG
PepGen
2.9109 of 5 stars
$1.53
+1.3%
$9.67
+531.8%
-89.5%$50.06MN/A-0.5130Gap Down
CUE
Cue Biopharma
3.8678 of 5 stars
$0.77
+2.3%
$3.00
+290.7%
-63.0%$47.47M$9.29M-0.8560
ATNM
Actinium Pharmaceuticals
1.1845 of 5 stars
$1.52
-1.9%
$4.00
+163.2%
N/A$47.42M$81,000.00-1.0930Trending News
Gap Down

Related Companies and Tools


This page (NASDAQ:FLKS) was last updated on 5/23/2025 by MarketBeat.com Staff
From Our Partners